Chinese medical devices major
Mindray Medical International Limited
) recently revealed that it will showcase over 60 offerings at
the 69th China International Medical Equipment Fair to be held in
Shenzhen, China during April 17 and April 20, 2013. Mindray will
exhibit its most current offerings from each of its three
segments, namely medical imaging systems, patient monitoring and
life support and in-vitro diagnostic. Besides, the company will
showcase certain offerings from units that it has acquired
The outlook for Mindray is favorable. The company forecasts
revenue growth of 17% or more for 2013. It also expects adjusted
net income for the year to increase by a minimum of 15% year over
Mindray is a bellwether in the Chinese MedTech industry with a
solid international presence. A key distinction with domestic
competitors is that the majority of Mindray's products have CE
Mark and/or Food and Drug Administration (FDA) clearance.
Mindray maintains a decent product pipeline and brings out
several new products each year. New products contribute in a
major way to Mindray's revenues. In 2012, the company launched 10
new products and acquired four companies.
The company has entered the premium segment globally, where
its competitive advantage is still unclear. Also, on the negative
side, health care reforms in China and the U.S. may reduce demand
for Mindray's products. Competition is fierce and leads to price
erosion over time.
The stock carries a Zacks Rank #2 (Buy).
Given Imaging Ltd.
) each carry a Zacks Rank #1 (Strong Buy) and are expected to do
CEPHEID INC (CPHD): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
GIVEN IMAGING (GIVN): Free Stock Analysis
MINDRAY MEDICAL (MR): Free Stock Analysis
To read this article on Zacks.com click here.